Quick Answer
Barinthus Biotherapeutics plc. reported Total Revenue of $0.00 for fiscal year 2025.
Barinthus Biotherapeutics plc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$14.97M +1766.5% |
$802.0K -98.2% |
$44.70M +16580.2% |
$268.0K -94.4% |
$4.82M |
| Revenue (ASC 606) | $0.00 -100.0% |
$14.97M +1766.5% |
$802.0K -98.2% |
$44.70M +16580.2% |
$268.0K -94.4% |
$4.82M |
| Net Income | -$66.43M -8.8% |
-$61.07M +16.7% |
-$73.35M -1473.0% |
$5.34M +110.5% |
-$50.87M -187.3% |
-$17.71M |
| Diluted EPS | -$1.64 -5.8% |
-$1.55 +18.8% |
-$1.91 -1464.3% |
$0.14 +107.1% |
-$1.96 +12.5% |
-$2.24 |
| Total Assets | $98.17M -38.8% |
$160.33M -25.3% |
$214.51M -20.6% |
$270.20M -3.7% |
$280.71M +454.1% |
$50.67M |
| Cash and Equivalents | $70.46M -36.3% |
$110.66M -22.1% |
$142.09M -26.9% |
$194.38M -9.2% |
$214.05M +394.7% |
$43.27M |
| Stockholders Equity | $74.21M -42.9% |
$130.03M -30.4% |
$186.78M -23.1% |
$242.90M -3.7% |
$252.12M +783.0% |
-$36.91M -67.2% |
| R&D Expense | $25.56M -39.5% |
$42.24M -5.9% |
$44.87M +6.0% |
$42.35M +107.9% |
$20.37M +41.6% |
$14.39M |
| Operating Income | -$70.56M -3.8% |
-$67.97M +19.0% |
-$83.91M -1976.6% |
-$4.04M +91.1% |
-$45.22M -125.6% |
-$20.05M |
| Shares Outstanding | 40.85M +1.5% |
40.23M +4.1% |
38.64M +2.5% |
37.68M +1.3% |
37.19M +367.2% |
7.96M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Revenue (ASC 606) | September 30, 2025 | $0.00 | -100.0% | -100.0% |
| Net Income | September 30, 2025 | -$14.57M | -79.5% | +31.0% |
| Diluted EPS | September 30, 2025 | -$0.36 | -71.4% | +30.8% |
| Total Assets | September 30, 2025 | $109.20M | -42.1% | -15.7% |
| Cash and Equivalents | September 30, 2025 | $74.27M | — | -13.9% |
| Stockholders Equity | September 30, 2025 | $84.47M | -47.0% | -17.5% |
| R&D Expense | September 30, 2025 | $5.39M | -51.6% | -32.2% |
| Operating Income | September 30, 2025 | -$15.07M | -60.6% | +35.4% |
| Shares Outstanding | September 30, 2025 | 40.83M | +3.2% | +1.2% |
- Barinthus Biotherapeutics plc. reported Total Revenue of $0.00 for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Barinthus Biotherapeutics plc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Barinthus Biotherapeutics plc. reported Net Income of -$66.43 million for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -8.8% in Net Income compared to the prior fiscal year.
- Barinthus Biotherapeutics plc. reported Diluted EPS of $1.64 per share (loss) for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -5.8% in Diluted EPS compared to the prior fiscal year.
- Barinthus Biotherapeutics plc. reported Total Assets of $98.17 million for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -38.8% in Total Assets compared to the prior fiscal year.
- Barinthus Biotherapeutics plc. reported Cash and Equivalents of $70.46 million for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -36.3% in Cash and Equivalents compared to the prior fiscal year.
- Barinthus Biotherapeutics plc. reported Stockholders Equity of $74.21 million for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -42.9% in Stockholders Equity compared to the prior fiscal year.
- Barinthus Biotherapeutics plc. reported R&D Expense of $25.56 million for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -39.5% in R&D Expense compared to the prior fiscal year.
- Barinthus Biotherapeutics plc. reported Operating Income of -$70.56 million for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -3.8% in Operating Income compared to the prior fiscal year.
- Barinthus Biotherapeutics plc. reported Shares Outstanding of 40.85 million shares for fiscal year 2025.
- Barinthus Biotherapeutics plc. showed an increase of +1.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: